Metrics other than potency reveal systematic variation in responses to cancer drugs - Dataset (ID:20120)
Download: Excel (XLSX), Comma-separated (CSV)
| Small Molecule | Cell Line | log10[max. dose (M)] | R^2 (goodness of fit) | log10[EC50 (M)] | log10[IC50 (M)] | log10[GI50 (M)] | HillSlope | E_inf | E_max | AUC |
|---|---|---|---|---|---|---|---|---|---|---|
| Fascaplysin | 184A1 | -4.4776 | 0.9829 | -6.3051 | -6.3045 | -6.4382 | 2.4270 | 0.0007 | 0.0007 | 5.9730 |
| Triciribine | 184A1 | -4.4776 | 0.9806 | -6.7336 | -6.6062 | -7.0537 | 0.9426 | 0.1206 | 0.1272 | 5.7766 |
| XRP44X | 184A1 | -3.8761 | 0.9432 | -6.8881 | -3.8761 | -6.4727 | 1.3400 | 0.6235 | 0.6235 | 7.2068 |
| Gemcitabine | 184A1 | -3.8416 | 0.8958 | -4.9646 | -4.8599 | -6.3316 | 0.4675 | 0.0532 | 0.2709 | 6.6571 |
| Omipalisib | 184A1 | -4.4776 | 0.9136 | -8.6666 | -8.1611 | -8.7804 | 0.9289 | 0.3302 | 0.3303 | 4.7168 |
| Vorinostat | 184A1 | -1.7282 | 0.9624 | -3.5347 | -3.4273 | -3.8929 | 0.7632 | 0.0877 | 0.1295 | 6.3101 |
| (Z)-4-Hydroxytamoxifen | 184A1 | -3.7773 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | 8.4030 |
| Bosutinib | 184A1 | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN | NaN |
| Carboplatin | 184A1 | -2.8697 | 0.9549 | -4.7112 | -4.6379 | -4.9293 | 2.5095 | 0.1727 | 0.1727 | 6.2179 |
| Tozasertib | 184A1 | -4.0000 | 0.9510 | -5.1140 | -5.1141 | -5.7005 | 0.5227 | 0.0000 | 0.2074 | 6.6019 |
| Topotecan | 184A1 | -3.9626 | 0.8916 | -6.6386 | -6.1231 | -7.0810 | 0.8042 | 0.3075 | 0.3124 | 5.8239 |
| NSC 663284 | 184A1 | -3.7773 | 0.9832 | -5.6953 | -5.6942 | -5.7830 | 3.9990 | 0.0079 | 0.0079 | 5.7685 |
| GSK1838705A | 184A1 | -4.1759 | 0.9532 | -6.4634 | -6.1300 | -6.4424 | 1.9500 | 0.3760 | 0.3760 | 6.8062 |
| Ibandronate | 184A1 | -2.8239 | 0.9791 | -3.6425 | -3.6426 | -3.8459 | 1.8340 | 0.0000 | 0.0305 | 7.2563 |